company background image
MYGN logo

Myriad Genetics NasdaqGS:MYGN Stock Report

Last Price

US$22.72

Market Cap

US$2.0b

7D

-2.3%

1Y

22.5%

Updated

24 Feb, 2024

Data

Company Financials +

Myriad Genetics, Inc.

NasdaqGS:MYGN Stock Report

Market Cap: US$2.0b

MYGN Stock Overview

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.

MYGN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Myriad Genetics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Myriad Genetics
Historical stock prices
Current Share PriceUS$22.72
52 Week HighUS$24.21
52 Week LowUS$13.82
Beta2
1 Month Change2.81%
3 Month Change26.08%
1 Year Change22.55%
3 Year Change-25.48%
5 Year Change-26.33%
Change since IPO322.70%

Recent News & Updates

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Recent updates

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Dec 18
Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Aug 07
Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Apr 13
Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Myriad: Trying To Find Its Footing In An Evolving Industry

Sep 26

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Aug 25

Are Investors Undervaluing Myriad Genetics, Inc. (NASDAQ:MYGN) By 50%?

Aug 05
Are Investors Undervaluing Myriad Genetics, Inc. (NASDAQ:MYGN) By 50%?

Myriad Genetics Q2 2022 Earnings Preview

Aug 03

Myriad Genetics touts study results of GeneSight test on depression remission rates

Jul 12

Myriad Genetics' (NASDAQ:MYGN) Solid Profits Have Weak Fundamentals

Aug 11
Myriad Genetics' (NASDAQ:MYGN) Solid Profits Have Weak Fundamentals

Shareholder Returns

MYGNUS BiotechsUS Market
7D-2.3%1.5%1.3%
1Y22.5%10.5%25.6%

Return vs Industry: MYGN exceeded the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: MYGN underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is MYGN's price volatile compared to industry and market?
MYGN volatility
MYGN Average Weekly Movement7.1%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: MYGN has not had significant price volatility in the past 3 months.

Volatility Over Time: MYGN's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19912,600Paul Diazhttps://myriad.com

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

Myriad Genetics, Inc. Fundamentals Summary

How do Myriad Genetics's earnings and revenue compare to its market cap?
MYGN fundamental statistics
Market capUS$2.01b
Earnings (TTM)-US$274.40m
Revenue (TTM)US$734.40m

2.7x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MYGN income statement (TTM)
RevenueUS$734.40m
Cost of RevenueUS$228.50m
Gross ProfitUS$505.90m
Other ExpensesUS$780.30m
Earnings-US$274.40m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 27, 2024

Earnings per share (EPS)-3.09
Gross Margin68.89%
Net Profit Margin-37.36%
Debt/Equity Ratio5.6%

How did MYGN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.